Journal of the American Chemical Society
Communication
isocyanates, see: Tsui, G. C.; Ninnemann, N. M.; Hosotani, A.;
Lautens, M. Org. Lett. 2013, 15, 1064.
(9) For the first report of an isocyanate metathesis reaction, see:
ASSOCIATED CONTENT
■
S
* Supporting Information
Experimental procedures, spectral data and copies of the
spectra. This material is available free of charge via the
Case, L. C. Nature 1959, 183, 675.
(10) Franz, J. A.; Martin, J. C. J. Am. Chem. Soc. 1975, 97, 583.
(11) For examples of the metathesis reaction between nitrogen-
phosphorus ylides and carbon dioxide, see: (a) Molina, P.; Alajarin,
M.; Arques, A. Synthesis 1982, 596. (b) Tsuge, O.; Kanemasa, S.;
Matsuda, K. J. Org. Chem. 1984, 49, 2688. (c) Charbonnier, F.;
AUTHOR INFORMATION
■
Corresponding Author
Marsura, A.; Roussel, K.; Kovac
84, 535.
́ ́
s, J.; Pinter, I. Helv. Chim. Acta 2001,
(12) Interestingly, attempts to utilize phosphonium ylides in the
metal-catalyzed allylic substitution reaction were unsuccessful thereby
making the sulfilimine critical for this process.
Notes
The authors declare no competing financial interest.
(13) For the definition of conservation of enantiomeric excess (cee),
see: Evans, P. A.; Robinson, J. E.; Nelson, J. D. J. Am. Chem. Soc.
1999, 121, 6761.
(14) For enthalpies of formation of various isocyanates, see:
Selivanov, V. D.; Konstantinov, I. I. Russ. J. Phys. Ch. 1975, 49, 620.
Unfortunately, the corresponding enthalpies of formation of aryl
sulfilimines are not available.
(15) Toxicity: LC50 (inhalation) in male rats for phosgene = 49
mg/m3 and MDI = 369 mg/m3. Alternatively, the amount that is
immediately dangerous to life or health for phosgene = 8.1 mg/m3
and MDI = 75 mg/m3. See: Hazardous Substances Data Bank
(16) Cost: Selected prices for Phosgene = 2.26; Diphosgene = 5.91;
PIC = 0.19; 4,4′-MDI = 0.07 ($/g, USD, Aldrich).
(17) Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. J.
Am. Chem. Soc. 2003, 125, 11360.
ACKNOWLEDGMENTS
■
We sincerely thank the National Sciences and Engineering
Research Council (NSERC) for a Discovery Grant and
Queen’s University for generous financial support. NSERC
is also thanked for supporting a Tier 1 Canada Research Chair
(P.A.E.). Additionally, we acknowledge the Royal Society for a
Wolfson Research Merit Award (P.A.E.).
REFERENCES
■
(1) Braverman, S.; Cherkinsky, M.; Birsa, M. L. In Science of
Synthesis; Ley, S. V., Noyori, R., Knight, J. G., Eds.; Thieme:
Stuttgart, Germany, 2005; Vol. 18, p 83.
(2) For examples of enantiomerically enriched isocyanates in the
prepraration of medicinally important drugs, see: (a) Cystic Fibrosis:
Storace, L.; Anzalone, L.; Confalone, P. N.; Davis, W. P.; Fortunak, J.
M.; Giangiordano, M.; Haley, J. J., Jr.; Kamholz, K.; Li, H.-Y.; Ma, P.;
Nugent, W. A.; Parsons, R. L., Jr.; Sheeran, P. J.; Silverman, C. E.;
Waltermire, R. E.; Wood, C. G. Org. Process Res. Dev. 2002, 6, 54.
(b) Alzheimer’s Disease: Boy, K. M.; Guernon, J. M.; Shi, J.; Toyn,
J. H.; Meredith, J. E.; Barten, D. M.; Burton, C. R.; Albright, C. F.;
Marcinkeviciene, J.; Good, A. C.; Tebben, A. J.; Muckelbauer, J. K.;
Camac, D. M.; Lentz, K. A.; Bronson, J. J.; Olson, R. E.; Macor, J. E.;
Thompson, L. A., III. Bioorg. Med. Chem. Lett. 2011, 21, 6916. (c)
Influenza: Charifson, P.; Clark, M. P.; Bandarage, U. P.; Deng, H.;
Davies, I.; Duffy, J. P.; Farmer, L. J.; Gao, H.; Gu, W.; Kennedy, J.
M.; Ledeboer, M. W.; WO 2012/083122 A1 PCT Int. Appl. 2007.
(3) For recent examples of the stereoselective and stereospecific
[3,3]-rearrangement of primary allylic carbamates, see: (a) Roulland,
(18) Naasz, R.; Arnold, L. A.; Minnaard, A. J.; Feringa, B. L. Angew.
Chem., Int. Ed. 2001, 40, 927.
́
E.; Monneret, C.; Florent, J.-C.; Bennejean, C.; Renard, P.; Leonce,
S. J. Org. Chem. 2002, 67, 4399. (b) Roy, S.; Spino, C. Org. Lett.
2006, 8, 939. (c) Ichikawa, Y.; Matsuda, Y.; Okumura, K.; Nakamura,
M.; Masuda, T.; Kotsuki, H.; Nakano, K. Org. Lett. 2011, 13, 2520.
(4) For recent examples of the stereopecific Curtius rearrangement
of β,γ-unsaturated carboxylic acids, see: (a) Honda, T.; Koizumi, T.;
Komatsuzaki, Y.; Yamashita, R.; Kanai, K.; Nagase, H. Tetrahedron:
Asymmetry 1999, 10, 2703. (b) Ravn, M. M.; Peters, R. J.; Coates, R.
M.; Croteau, R. J. Am. Chem. Soc. 2002, 124, 6998.
(5) For examples that utilize phosgene and phosgene equivalents,
see: (a) Keyes, R. F.; Carter, J. J.; Zhang, X.; Ma, Z. Org. Lett. 2005,
7, 847. (b) van der Linden, W. A.; Willems, L. I.; Shabaneh, T. B.;
Li, N.; Ruben, M.; Florea, B. I.; van der Marel, G. A.; Kaiser, M.;
Kisselev, A. F.; Overkleeft, H. S. Org. Biomol. Chem. 2012, 10, 181.
(6) For alternative methods for the construction of aryl, benzyl and
allylic isocyanates via metal-catalyzed carbonylation and cross-
coupling reactions, see: (a) Vinogradova, E. V.; Fors, B. P.;
Buchwald, S. L. J. Am. Chem. Soc. 2012, 134, 11132. (b) Ren, L.;
Jiao, N. Chem. Commun. 2014, 50, 3706.
(7) For leading references on the asymmetric allylic amination with
aza-ylides, see: (a) Rh: Evans, P. A.; Clizbe, E. A. J. Am. Chem. Soc.
2009, 131, 8722. (b) Ir: Grange, R. L.; Clizbe, E. A.; Counsell, E. J.;
Evans, P. A. Chem. Sci. 2014, DOI: 10.1039/c4sc01317d.
(8) For an example of the challenges associated with the
enantioselective metal-catalyzed allylic substitution with alkali-metal
D
dx.doi.org/10.1021/ja504631v | J. Am. Chem. Soc. XXXX, XXX, XXX−XXX